Latest Industry Insights

Dr. Christian Landles explains why it is so challenging to develop therapeutics for rare diseases such as HD, and discusses the potential of approaches that target mutant huntingtin protein to improve treatment options for HD patients.

Dr. Christian Landles highlights some of the progress made in recent years to improve our understanding of HD and its drivers.

Psychedelic-assisted psychotherapy (PAP) is under investigation for its potential in treating psychiatric conditions. A recent paper, published by academics Agnieszka Sekula and Dr. Prash Puspanathan, outlined how virtual reality (VR) might be incorporated into aspects of the PAP process.

The intricate and intertwined nature of the host‒microbiota connection has garnered increasing interest from the scientific community in recent years, due to its known role in the development and progression of various diseases. 4D pharma has leveraged growing knowledge in the field, by creating a novel class of medicines called live biotherapeutic products (LBPs).

Technology Networks spoke to Renee Ryan, Cala Health's CEO, to learn more about bioelectronic medicine and its use as a therapy for essential tremors.

For the world’s leading neuroscientists, unlocking the brain’s capacity to stimulate neural plasticity has become something of a Holy Grail. In this Insight, NervGen Pharma president and CEO Paul Brennan details why plasticity is so important for the brain.

In this interview, Jim Ross highlights several recent examples of how bioelectronic assays are helping to advance drug discovery for neurological diseases ranging from pediatric epilepsy to Burning Man Syndrome.

Emulate's chief scientific officer, Dr. Lorna Ewart, talks about inspiring a new generation of women in STEM.

Unpicking our brain's complexity at a cellular level is a mammoth task. How do our genes, cells and electrical impulses come together to decode the world around us? At Boston University Assistant Professor Jerry Chen is trying to crack this code. In this interview, we speak to Chen about his study’s aims, findings and implications.

Technology Networks spoke to Atara’s chief medical officer, AJ Joshi, to learn more about ATA188 – an off-the-shelf, allogeneic T-cell immunotherapy – and how it could revolutionize treatment for MS patients.